Cannabix Technologies Inc. reveals new advancements in cannabis use detecting breathalyzer technology.
Image | adobe.stock/Mitch
Cannabix Technologies Inc. (Cannabix), announced in a recent press release (1), that their Cannabix Marijuana Breathalyzer (CMB) technology received important updates which will help them “meet suggested emerging regulatory requirements in preparation for marketing,” (1). Engineers were able to update the Breath Collection Unit (BCU) through a variety of features. The BCU is a tool that is utilized for collecting delta-9 tetrahydrocannabinol (THC) portably. The technology updates were influenced by the rise in cannabis breath detection being seen in the United States (US), as well as globally (1).
The New York Times recently published an article titled, “As Marijuana Use Grows, Effect on Road Safety Remains a Blind Spot,” (2). The article brings a spotlight to the challenges such as the “lack of tools” to identify drivers that may be cannabis-impaired (2). According to a 2019 survey by the AAA Foundation for Traffic Safety (2,3), “…an estimated 14.8 million drivers (in the U.S) reported getting behind the wheel within one hour after using marijuana, and 70% of Americans thinking it’s unlikely a driver will get caught by police for driving while high on marijuana.” Some of the methods used to detect cannabis use are saliva, urine, and blood. As mentioned in the press release (1), the breathalyzer technology from Cannabix seeks to detect the presence of cannabis through “recent use detection of delta-9 THC.”
Rav Mlait, CEO of Cannabix said (1), “Cannabix is at the forefront of marijuana breathalyzer technology, and we anticipate that 2025 will hold significant milestones as the Company has matured its technology, partnerships and business opportunities. In the U.S., cannabis legalization has grown to 39 states for medical use and 24 states legalized for recreational use. This represents a major growth opportunity for Cannabix in the drug testing segment.”
Below are some of the highlights listed in the press release (1):
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.